Farmacias is Sole Recipient of Federal License
to Import, Formulate, Store and Sell Medical Cannabis
Containing THC
TSX | NYSE: ACB
EDMONTON, Dec. 7, 2018 /PRNewswire/ - Aurora Cannabis
Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB)
(Frankfurt: 21P; WKN: A1C4WM)
announced today that the Company has established an exclusive
partnership with Farmacias Magistrales S.A. ("Farmacias"), an
established Mexican pharmaceutical manufacturer and distributer
with a broad reach to approximately 80,000 retail points and 500
pharmacies and hospitals across Mexico. Farmacias recently received the first
and only import license granted to date, from the Federal
Commission for Protection Against Health Risks ("COFEPRIS"), the
Mexican government body responsible for medical cannabis licensing,
which permits Farmacias to import Aurora medical cannabis products
containing THC into Mexico.
Farmacias has also received licenses from COFEPRIS to
permit:
- Importation and storage of raw CBD and THC materials
- Manufacture of CDB and THC products
- Distribution of CBD and THC products
Farmacias' license to import Aurora's medical cannabis into
Mexico positions Aurora with
another first-mover advantage in one of the world's most populous
countries, where more than 130 million people will have federally
legal access to a range of Aurora's non-flower medical cannabis
products containing THC and/or CBD. Dried flower containing THC is
currently prohibited for domestic cultivation, import or sale in
Mexico.
Management Commentary
"This new exclusive partnership further expands Aurora's early
mover advantage in Latin America,
allowing us to become a leading player in the development of the
medical cannabis system in Mexico,
a legal market of 130 million people," said Terry Booth, CEO of Aurora. "We look forward to
working with Farmacias, and leveraging its strong retail, pharmacy,
and hospital networks to provide high-quality, medical grade
cannabis to patients in this new and significant market. We will
also offer the Mexican government authorities whatever support they
deem valuable, based on our insights and experience earned from
operating in multiple nationally-legal medical cannabis systems
around the world. "
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 22 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland, have achieved this level of
certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland , H2 Biopharma, Urban
Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed
Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia,
Agropro, Borela, and the pending acquisition of ICC Labs – Aurora
is distinguished by its reputation as a partner and employer of
choice in the global cannabis sector, having invested in and
established strategic partnerships with a range of leading
innovators, including: Radient Technologies Inc. (TSXV: RTI),
Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX:
CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings
Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group
(private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and include, but are not limited to the
variety of cannabis products that Aurora will supply to the adult
use market.. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither the TSX, NYSE nor their Regulation Services
Provider (as that term is defined in the policies of the TSX and
NYSE) accepts responsibility for the adequacy or accuracy of this
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-to-enter-mexico-market-via-exclusive-supply-arrangement-with-farmacias-magistrales-300762006.html
SOURCE Aurora Cannabis Inc.